Propanc Biopharma, Inc. (PPCB)

276,567% (1Y)

Market Cap	77.10M
Revenue (ttm)	n/a
Net Income (ttm)	-55.39M
Shares Out	11.61M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114
Average Volume	1,869
Open	6.00
Previous Close	5.58
Day's Range	6.00 - 6.64
52-Week Range	0.00 - 145.46
Beta	19,161.25
RSI	65.93
Earnings Date	May 15, 2025

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research collaboration with University of Jaén to carry out a research project aimed at the synthetic development of PRP and its subsequent validation; and a joint ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2
• Stock Exchange: OTCMKTS
• Ticker Symbol: PPCB